VERV - Biotechs rally with gene editing stocks among notable gainers
2023-11-03 15:23:43 ET
More on XBI and IBB
- Biopharma Bounce-Back: From Policy Pains To Profitable Plains
- IBB: The Illness Of Idiosyncratic Risk
- Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns
- Citi turns cautious on pharmaceuticals and biotech
- Seeking Alpha’s Quant Rating on iShares Biotechnology ETF
For further details see:
Biotechs rally with gene editing stocks among notable gainers